Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma

Journal of Oncology

Volumn , Issue , 2010, Pages

  Rahman, Ruman ^a   Smith, Stuart ^a   Rahman, Cheryl ^a   Grundy, Richard ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; AFLIBERCEPT; AGOURON; AMG 102; BEVACIZUMAB; CARMUSTINE; CEDIRANIB; CELECOXIB; CILENGITIDE; ENZASTAURIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; IMATINIB; INTEGRIN; LENALIDOMIDE; NIMOTUZUMAB; PLATELET DERIVED GROWTH FACTOR B; POLYGLYCOLIC ACID; PRINOMASTAT; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLOOD BRAIN BARRIER; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG RESPONSE; EXTRACELLULAR MATRIX; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; HYPOXIA; INTESTINE PERFORATION; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN CLEAVAGE; PROTEIN TARGETING; QT PROLONGATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR RESISTANCE; TUMOR VASCULARIZATION;

EID: 77952509640     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/251231     Document Type: Review

References (169)

1. David N., Louis M. D., Ohgaki H., Wiestler O. D., Cavenee W. K., WHO Classification of Tumours of the Central Nervous System 2007 4th IARC Press
2. Stummer W., Reulen H.-J., Meinel T., Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias Neurosurgery 2008 62 3 564 576
3. Wisoff J. H., Boyett J. M., Berger M. S., Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Childrens Cancer Group Trial No. CCG-945 Journal of Neurosurgery 1998 89 1 52 59
4. Stupp R., Mason W. P., van den Bent M. J., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma The New England Journal of Medicine 2005 352 10 987 996
5. Pollack I. F., Brain tumors in children The New England Journal of Medicine 1994 331 22 1500 1507
6. Grundy R. G., Wilne S. H., Robinson K. J., Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial European Journal of Cancer 2010 46 1 120 133
7. Liang Y., Diehn M., Watson N., Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme Proceedings of the National Academy of Sciences of the United States of America 2005 102 16 5814 5819
8. McLendon R., Friedman A., Bigner D., Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 2008 455 7216 1061 1068
9. Karcher S., Steiner H.-H., Ahmadi R., Different angiogenic phenotypes in primary and secondary glioblastomas International Journal of Cancer 2006 118 9 2182 2189
10. Tate M. C., Aghi M. K., Biology of angiogenesis and invasion in glioma Neurotherapeutics 2009 6 3 447 457
11. Risau W., Flamme I., Vasculogenesis Annual Review of Cell and Developmental Biology 1995 11 73 91
12. Brem S., Cotran R., Folkman J., Tumor angiogenesis: a quantitative method for histologic grading Journal of the National Cancer Institute 1972 48 2 347 356
13. Folkman J., Angiogenesis Annual Review of Medicine 2006 57 1 18
14. Brown J. M., Wilson W. R., Exploiting tumour hypoxia in cancer treatment Nature Reviews Cancer 2004 4 6 437 447
15. Wang D., Anderson J. C., Gladson C. L., The role of the extracellular matrix in angiogenesis in malignant glioma tumors Brain Pathology 2005 15 4 318 326
16. Hanahan D., Bergers G., Bergsland E., Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice Journal of Clinical Investigation 2000 105 8 1045 1047
17. Reiss Y., Machein M. R., Plate K. H., The role of angiopoietins during angiogenesis in gliomas Brain Pathology 2005 15 4 311 317
18. Zagzag D., Amirnovin R., Greco M. A., Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis Laboratory Investigation 2000 80 6 837 849
19. Zagzag D., Zhong H., Scalzitti J. M., Laughner E., Simons J. W., Semenza G. L., Expression of hypoxia-inducible factor 1 in brain tumors: association with angiogenesis, invasion, and progression Cancer 2000 88 11 2606 2618
20. Semenza G. L., Hypoxia-inducible factor 1: master regulator of O2 homeostasis Current Opinion in Genetics and Development 1998 8 5 588 594
21. Plate K. H., Breier G., Weich H. A., Mennel H. D., Risau W., Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms International Journal of Cancer 1994 59 4 520 529
22. Plate K. H., Breier G., Weich H. A., Risau W., Vascular endothelial growth factor is a potential tumour angiogenssis factor in human gliomas in vivo Nature 1992 359 6398 845 848
23. Guo P., Imanishi Y., Cackowski F. C., Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 2 correlates with the invasiveness of human glioma American Journal of Pathology 2005 166 3 877 890
24. Rao J. S., Yamamoto M., Mohaman S., Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas Clinical and Experimental Metastasis 1996 14 1 12 18 (Pubitemid 26009751)
25. Serini G., Valdembri D., Bussolino F., Integrins and angiogenesis: a sticky business Experimental Cell Research 2006 312 5 651 658
26. Carmeliet P., VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nature Medicine 2000 6 10 1102 1103
27. Machein M. R., Plate K. H., VEGF in brain tumors Journal of Neuro-Oncology 2000 50 1-2 109 120
28. Safran M., Kaelin W. G. Jr., HIF hydroxylation and the mammalian oxygen-sensing pathway Journal of Clinical Investigation 2003 111 6 779 783
29. Guo P., Hu B., Gu W., Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment American Journal of Pathology 2003 162 4 1083 1093
30. Pertovaara L., Kaipainen A., Mustonen T., Vascular endothelial growth factor is induced in response to transforming growth factor-in fibroblastic and epithelial cells Journal of Biological Chemistry 1994 269 9 6271 6274
31. Tsai J.-C., Goldman C. K., Gillespie G. Y., Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF Journal of Neurosurgery 1995 82 5 864 873
32. Jain R. K., di Tomaso E., Duda D. G., Loeffler J. S., Sorensen A. G., Batchelor T. T., Angiogenesis in brain tumours Nature Reviews Neuroscience 2007 8 8 610 622
33. Gerber H.-P., Dixit V., Ferrara N., Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells Journal of Biological Chemistry 1998 273 21 13313 13316 (Pubitemid 28246905)
34. Gerber H.-P., McMurtrey A., Kowalski J., Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation Journal of Biological Chemistry 1998 273 46 30336 30343
35. Ueba T., Takahashi J. A., Fukumoto M., Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues Neurosurgery 1994 34 2 221 226
36. Yamada S. M., Yamada S., Hayashi Y., Takahashi H., Teramoto A., Matsumoto K., Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas Neurological Research 2002 24 3 244 248
37. Bergers G., Song S., The role of pericytes in blood-vessel formation and maintenance Neuro-Oncology 2005 7 4 452 464
38. Ferrara N., VEGF as a therapeutic target in cancer Oncology 2005 69 supplement 3 11 16
39. Roberts W. G., Whalen P. M., Soderstrom E., Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451 Cancer Research 2005 65 3 957 966
40. Slowik M. R., De Luca L. G., Fiers W., Pober J. S., Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration American Journal of Pathology 1993 143 6 1724 1730
41. Ryuto M., Ono M., Izumi H., Induction of vascular endothelial growth factor by tumor necrosis factor in human glioma cells: possible roles of SP-1 Journal of Biological Chemistry 1996 271 45 28220 28228
42. DAbaco G. M., Kaye A. H., Integrins: molecular determinants of glioma invasion Journal of Clinical Neuroscience 2007 14 11 1041 1048
43. Stromblad S., Cheresh D. A., Integrins, angiogenesis and vascular cell survival Chemistry and Biology 1996 3 11 881 885
44. Forsyth P. A., Wong H., Laing T. D., Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas British Journal of Cancer 1999 79 11-12 1828 1835
45. Rao J. S., Sawaya R., Gokaslan Z. L., Yung W. K. A., Goldstein G. W., Laterra J., Modulation of serine proteinases and metalloproteinases during morphogenic glial-endothelial interactions Journal of Neurochemistry 1996 66 4 1657 1664
46. Wick W., Platten M., Weller M., Glioma cell invasion: regulation of metalloproteinase activity by TGF-Journal of Neuro-Oncology 2001 53 2 177 185
47. Yu Q., Stamenkovic I., Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-and promotes tumor invasion and angiogenesis Genes and Development 2000 14 2 163 176
48. Anderson J. C., Mcfarland B. C., Gladson C. L., New molecular targets in angiogenic vessels of glioblastoma tumours Expert Reviews in Molecular Medicine 2008 10, article e23
49. Joe Y.-A., Hong Y.-K., Chung D.-S., Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 13 International Journal of Cancer 1999 82 5 694 699
50. Kirsch M., Strasser J., Allende R., Bello L., Zhang J., Black P. M., Angiostatin suppresses malignant glioma growth in vivo Cancer Research 1998 58 20 4654 4659
51. Adams J. C., Lawler J., The thrombospondins International Journal of Biochemistry and Cell Biology 2004 36 6 961 968
52. Simantov R., Silverstein R. L., CD36: a critical anti-angiogenic receptor Frontiers in Bioscience 2003 8 supplement 3 s874 s882
53. Anderson J. C., Grammer J. R., Wang W., ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis Cancer Biology and Therapy 2007 6 3 454 462
54. Strik H. M., Weller M., Frank B., Heat shock protein expression in human gliomas Anticancer Research 2000 20 6 B 4457 4462
55. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R., Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by v and 5 1 integrins Proceedings of the National Academy of Sciences of the United States of America 2003 100 8 4766 4771
56. Giese A., Westphal M., Glioma invasion in the central nervous system Neurosurgery 1996 39 2 235 252
57. Ernst A., Hofmann S., Ahmadi R., Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival Clinical Cancer Research 2009 15 21 6541 6550
58. Lim D. A., Cha S., Mayo M. C., Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype Neuro-Oncology 2007 9 4 424 429
59. Norden A. D., Drappatz J., Wen P. Y., Novel anti-angiogenic therapies for malignant gliomas The Lancet Neurology 2008 7 12 1152 1160
60. Kreisl T. N., Kim L., Moore K., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma Journal of Clinical Oncology 2009 27 5 740 745
61. Vredenburgh J. J., Desjardins A., Herndon J. E. II, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme Journal of Clinical Oncology 2007 25 30 4722 4729 (Pubitemid 350086473)
62. Desjardins A., Reardon D. A., Herndon J. E. II, Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas Clinical Cancer Research 2008 14 21 7068 7073
63. Gutin P. H., Iwamoto F. M., Beal K., Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas International Journal of Radiation Oncology Biology Physics 2009 75 1 156 163
64. Zuniga R. M., Torcuator R., Jain R., Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan Journal of Neuro-Oncology 2009 91 3 329 336
65. Yung W. K. A., Albright R. E., Olson J., A phase II study of temozolemide vs. procarbazine in patients with glioblastoma multiforme at first relapse British Journal of Cancer 2000 83 5 588 593
66. Quant E. C., Norden A. D., Drappatz J., Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-Oncology 2009 11 5 550 555
67. Sathornsumetee S., Cao Y., Marcello J. E., Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan Journal of Clinical Oncology 2008 26 2 271 278
68. Hsu J. Y., Wakelee H. A., Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy BioDrugs 2009 23 5 289 304
69. Norden A. D., Young G. S., Setayesh K., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 2008 70 10 779 787
70. Gagner J.-P., Law M., Fischer I., Newcomb E. W., Zagzag D., Angiogenesis in gliomas: imaging and experimental therapeutics Brain Pathology 2005 15 4 342 363
71. Holash J., Davis S., Papadopoulos N., VEGF-Trap: a VEGF blocker with potent antitumor effects Proceedings of the National Academy of Sciences of the United States of America 2002 99 17 11393 11398
72. Gomez-Manzano C., Holash J., Fueyo J., VEGF Trap induces antiglioma effect at different stages of disease Neuro-Oncology 2008 10 6 940 945
73. Krupitskaya Y., Wakelee H. A., Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer Current Opinion in Investigational Drugs 2009 10 6 597 605
74. Diaz Miqueli A., Rolff J., Lemm M., Fichtner I., Perez R., Montero E., Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies British Journal of Cancer 2009 100 6 950 958
75. Pillay V., Allaf L., Wilding A. L., The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases Neoplasia 2009 11 5 448 458
76. Batchelor T. T., Sorensen A. G., di Tomaso E., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 2007 11 1 83 95
77. Sorensen A. G., Batchelor T. T., Zhang W.-T., A vascular normalization index as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Research 2009 69 13 5296 5300
78. Herrington B., Kieran M. W., Small molecule inhibitors in children with malignant gliomas Pediatric Blood and Cancer 2009 53 3 312 317
79. Jane E. P., Premkumar D. R., Pollack I. F., Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells Journal of Pharmacology and Experimental Therapeutics 2006 319 3 1070 1080
80. Pouessel D., Culine S., High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor European Urology 2008 53 2 376 381
81. de Board S., Herlin P., Christensen J. G., Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma Neuro-Oncology 2007 9 4 412 423
82. Ebos J. M. L., Lee C. R., Cruz-Munoz W., Bjarnason G. A., Christensen J. G., Kerbel R. S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 2009 15 3 232 239
83. Pez-Ribes M., Allen E., Hudock J., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 2009 15 3 220 231
84. Goudar R. K., Shi Q., Hjelmeland M. D., Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Molecular Cancer Therapeutics 2005 4 1 101 112
85. Raymond E., Brandes A. A., Dittrich C., Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European organisation for research and treatment of cancer brain tumor group study Journal of Clinical Oncology 2008 26 28 4659 4665
86. Wen P. Y., Yung W. K. A., Lamborn K. R., Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 Clinical Cancer Research 2006 12 16 4899 4907
87. Reardon D. A., Egorin M. J., Desjardins A., Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma Cancer 2009 115 10 2188 2198
88. Milano V., Piao Y., Lafortune T., de Groot J., Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma Molecular Cancer Therapeutics 2009 8 2 394 406
89. Prados M. D., Chang S. M., Butowski N., Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma Journal of Clinical Oncology 2009 27 4 579 584
90. Fouladi M., Nicholson H. S., Zhou T., A Phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a childrens oncology group study Cancer 2007 110 11 2535 2541
91. Thatcher N., Chang A., Parikh P., Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) The Lancet 2005 366 9496 1527 1537
92. Kreisl T. N., Lassman A. B., Mischel P. S., A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) Journal of Neuro-Oncology 2009 92 1 99 105
93. Franceschi E., Cavallo G., Lonardi S., Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) British Journal of Cancer 2007 96 7 1047 1051
94. Graff J. R., McNulty A. M., Hanna K. R., The protein kinase C-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Research 2005 65 16 7462 7469
95. Kreisl T. N., Kim L., Moore K., A phase I trial of enzastaurin in patients with recurrent gliomas Clinical Cancer Research 2009 15 10 3617 3623
96. Galanis E., Buckner J. C., Maurer M. J., Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study Journal of Clinical Oncology 2005 23 23 5294 5304 (Pubitemid 46206983)
97. Wong M. L. H., Prawira A., Kaye A. H., Hovens C. M., Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas Journal of Clinical Neuroscience 2009 16 9 1119 1130
98. Fine H. A., Wen P. Y., Maher E. A., Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas Journal of Clinical Oncology 2003 21 12 2299 2304
99. Puduvalli V. K., Giglio P., Groves M. D., Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-Oncology 2008 10 2 216 222
100. Fadul C. E., Kingman L. S., Meyer L. P., A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme Journal of Neuro-Oncology 2008 90 2 229 235
101. Kesari S., Schiff D., Henson J. W., Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Neuro-Oncology 2008 10 3 300 308
102. Drappatz J., Wong E. T., Schiff D., A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme International Journal of Radiation Oncology Biology Physics 2009 73 1 222 227
103. Bissett D., OByrne K. J., von Pawel J., Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer Journal of Clinical Oncology 2005 23 4 842 849
104. Cloughesy T. F., Wen P. Y., Robins H. I., Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium study Journal of Clinical Oncology 2006 24 22 3651 3656
105. Lustig R., Mikkelsen T., Lesser G., Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease Neuro-Oncology 2008 10 6 1004 1009
106. Deroanne C. F., Bonjean K., Servotte S., Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling Oncogene 2002 21 3 427 436
107. Galanis E., Jaeckle K. A., Maurer M. J., Phase II trial of Vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study Journal of Clinical Oncology 2009 27 12 2052 2058
108. Kim S. H., Ahn S., Han J.-W., Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials Biochemical and Biophysical Research Communications 2004 315 4 964 970
109. Kieran M. W., Turner C. D., Rubin J. B., A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer Journal of Pediatric Hematology/Oncology 2005 27 11 573 581
110. Broniscer A., Baker S. J., Stewart C. F., Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma Clinical Cancer Research 2009 15 2 701 707
111. Pollack I. F., Jakacki R. I., Blaney S. M., Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report Neuro-Oncology 2007 9 2 145 160
112. Haas-Kogan D. A., Banerjee A., Kocak M., Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma Neuro-Oncology 2008 10 3 341 347
113. Kieran M. W., Supko J. G., Wallace D., Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors Pediatric Blood and Cancer 2009 52 2 169 176
114. Miller K. D., Sweeney C. J., Sledge G. W. Jr., Can tumor angiogenesis be inhibited without resistance? EXS 2005 94 95 112
115. Bergers G., Hanahan D., Modes of resistance to anti-angiogenic therapy Nature Reviews Cancer 2008 8 8 592 603
116. Glade Bender J., Cooney E. M., Kandel J. J., Yamashiro D. J., Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Drug Resistance Updates 2004 7 4-5 289 300
117. Kerbel R. S., Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results Journal of Clinical Oncology 2001 19 supplement 18 45S 51S
118. Kunkel P., Ulbricht U., Bohlen P., Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Cancer Research 2001 61 18 6624 6628
119. Rubenstein J. L., Kim J., Ozawa T., Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2000 2 4 306 314
120. Lucio-Eterovic A. K., Piao Y., de Groot J. F., Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Clinical Cancer Research 2009 15 14 4589 4599
121. Song S., Ewald A. J., Stallcup W., Werb Z., Bergers G., PDGFR + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival Nature Cell Biology 2005 7 9 870 879
122. Du R., Lu K. V., Petritsch C., HIF1 induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion Cancer Cell 2008 13 3 206 220
123. Blouw B., Song H., Tihan T., The hypoxic response of tumors is dependent on their microenvironment Cancer Cell 2003 4 2 133 146
124. Bao S., Wu Q., Sathornsumetee S., Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Research 2006 66 16 7843 7848
125. Folkins C., Shaked Y., Man S., Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1 Cancer Research 2009 69 18 7243 7251
126. Heddleston J. M., Li Z., McLendon R. E., Hjelmeland A. B., Rich J. N., The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype Cell Cycle 2009 8 20 3274 3284
127. Soeda A., Park M., Lee D., Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 Oncogene 2009 28 45 3949 3959
128. Tews D. S., Nissen A., Kulgen C., Gaumann A. K. A., Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors Journal of Neuro-Oncology 2000 50 3 227 237
129. 2+ and ABCG2-cancer cells are similarly tumorigenic Cancer Research 2005 65 14 6207 6219
130. Li Z., Bao S., Wu Q., Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells Cancer Cell 2009 15 6 501 513
131. Huse J. T., Brennan C., Hambardzumyan D., The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo Genes and Development 2009 23 11 1327 1337
132. Sasayama T., Nishihara M., Kondoh T., Hosoda K., Kohmura E., MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC International Journal of Cancer 2009 125 6 1407 1413
133. Xia H., Qi Y., Ng S. S., microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs Brain Research 2009 1269 C 158 165
134. Lawler S., Chiocca E. A., Emerging functions of microRNAs in glioblastoma Journal of Neuro-Oncology 2009 92 3 297 306
135. Northcott P. A., Fernandez-L A., Hagan J. P., The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors Cancer Research 2009 69 8 3249 3255
136. Kefas B., Godlewski J., Comeau L., microRNA-7 inhibits the epidermal growth factor receptor and the akt pathway and is down-regulated in glioblastoma Cancer Research 2008 68 10 3566 3572
137. Yunqing L., Guessous F., Ying Z., MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes Cancer Research 2009 69 19 7569 7576
138. Papagiannakopoulos T., Shapiro A., Kosik K. S., MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells Cancer Research 2008 68 19 8164 8172
139. Corbin R., Olsson-Carter K., Slack F., The role of microRNAs in synaptic development and function BMB Reports 2009 42 3 131 135
140. Erson A. E., Petty E. M., MicroRNAs in development and disease Clinical Genetics 2008 74 4 296 306
141. Wang S., Aurora A. B., Johnson B. A., The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis Developmental Cell 2008 15 2 261 271
142. Hua Z., Lv Q., Ye W., Mirna-directed regulation of VEGF and other angiogenic under hypoxia PLoS One 2006 1 1, article e116
143. Krtzfeldt J., Rajewsky N., Braich R., Silencing of microRNAs in vivo with antagomirs Nature 2005 438 7068 685 689
144. Kota J., Chivukula R. R., ODonnell K. A., Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model Cell 2009 137 6 1005 1017
145. Wrdinger T., Tannous B. A., Saydam O., miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells Cancer Cell 2008 14 5 382 393
146. Brown B. D., Naldini L., Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications Nature Reviews Genetics 2009 10 8 578 585
147. Gal H., Pandi G., Kanner A. A., MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells Biochemical and Biophysical Research Communications 2008 376 1 86 90
148. Uhrich K. E., Cannizzaro S. M., Langer R. S., Shakesheff K. M., Polymeric systems for controlled drug release Chemical Reviews 1999 99 11 3181 3198
149. Sawyer A. J., Piepmeier J. M., Saltzman W. M., New methods for direct delivery of chemotherapy for treating brain tumors Yale Journal of Biology and Medicine 2006 79 3-4 141 152
150. Fleming A. B., Saltzman W. M., Pharmacokinetics of the carmustine implant Clinical Pharmacokinetics 2002 41 6 403 419
151. Attenello F. J., Mukherjee D., Datoo G., Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience Annals of Surgical Oncology 2008 15 10 2887 2893
152. Seong H., An T. K., Khang G., Choi S.-U., Lee C. O., Lee H. B., BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro International Journal of Pharmaceutics 2003 251 1-2 1 12
153. Alonso M. J., Gupta R. K., Min C., Siber G. R., Langer R., Biodegradable microspheres as controlled-release tetanus toxoid delivery systems Vaccine 1994 12 4 299 306
154. Mullerad J., Cohen S., Voronov E., Apte R. N., Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres Cytokine 2000 12 11 1683 1690
155. Roullin V.-G., Lemaire L., Venier-Julienne M.-C., Faisant N., Franconi F., Benoit J.-P., Release kinetics of 5-fluorouracil-loaded microspheres on an experimental rat glioma Anticancer Research 2003 23 1A 21 25
156. Sanchez A., Gupta R. K., Alonso M. J., Siber G. R., Langer R., Pulsed controlled-release system for potential use in vaccine delivery Journal of Pharmaceutical Sciences 1996 85 6 547 552
157. Anderson J. M., Shive M. S., Biodegradation and biocompatibility of PLA and PLGA microspheres Advanced Drug Delivery Reviews 1997 28 1 5 24
158. Groothuis D. R., The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery Neuro-Oncology 2000 2 1 45 49
159. Wang P. P., Frazier J., Brem H., Local drug delivery to the brain Advanced Drug Delivery Reviews 2002 54 7 987 1013
160. Benny O., Duvshani-Eshet M., Cargioli T., Continuous delivery of endogenous inhibitors from poly (lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth Clinical Cancer Research 2005 11 2 768 776
161. Gil-Alegre M. E., Gonzalez-Alvarez I., Gutierrez-Pauls L., Torres-Suarez A. I., Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: development and activity against human glioblastoma cells Journal of Microencapsulation 2008 25 8 561 568
162. Kreuter J., Nanoparticulate systems for brain delivery of drugs Advanced Drug Delivery Reviews 2001 47 1 65 81
163. Calvo P., Gouritin B., Chacun H., Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery Pharmaceutical Research 2001 18 8 1157 1166 (Pubitemid 32900402)
164. Goppert T. M., Muller R. H., Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns Journal of Drug Targeting 2005 13 3 179 187
165. Kreuter J., Shamenkov D., Petrov V., Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier Journal of Drug Targeting 2002 10 4 317 325
166. Steiniger S. C. J., Kreuter J., Khalansky A. S., Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles International Journal of Cancer 2004 109 5 759 767
167. Ambruosi A., Gelperina S., Khalansky A., Tanski S., Theisen A., Kreuter J., Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model Journal of Microencapsulation 2006 23 5 582 592
168. Petri B., Bootz A., Khalansky A., Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants Journal of Controlled Release 2007 117 1 51 58
169. Gelperina S., Maksimenko O., Khalansky A., Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters European Journal of Pharmaceutics and Biopharmaceutics 2010 74 2 157 163